Skip to content

Application Research of Oliceridine in Pain Management for Elderly Patients after Laparoscopic Cholecystectomy

Application Research of Oliceridine in Pain Management for Elderly Patients after Laparoscopic Cholecystectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113135
Enrollment
Unknown
Registered
2025-11-25
Start date
2025-05-08
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Control group:Sufentanil

Sponsors

Shenzhen People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patient is aged 60 years or above; gender is not restricted. 2. ASA II-III grade. 3. Able to understand the VAS score. 4. Body Mass Index (BMI) is between 18 and 30 kg/m^2 (including the boundary values). 5. Vital signs during the screening period: respiratory rate >= 10 and = 95% when breathing air; systolic blood pressure (SBP) >= 90 mmHg and = 60 mmHg and =55 and <=100 beats per minute. 6. Understands the procedures and methods of this study, is willing to sign the informed consent form and strictly follow the trial protocol to complete this study.

Exclusion criteria

Exclusion criteria: 1. The patient is unconscious and has limited self-awareness; 2. Combined local anesthesia; 3. Conversion to open surgery; 4. It is expected that there will be difficulties in intubation or ventilation (modified Mallory score is level III or IV); 5. Before or during screening, any of the following respiratory management risks exist: 1) History of asthma; 2) Patients with sleep apnea syndrome; 3) COPD; 6. Chronic pain (for three months) or chronic use of analgesics (for three months); 7. Current or past drug addiction; 8. Participants who have participated in any drug clinical trials within the previous 1 month; 9. Use of drugs that may affect the QT interval within 2 weeks before or during screening; 10. Laboratory test indicators for the selection period meet the following standards: (1) AST and ALT >= 3×ULN; (2) TBIL >= 1.5×ULN;( 3) Hb = 1.5×ULN; 11.The investigators consider any participants with any other factors that are not suitable for participating in this trial.

Design outcomes

Primary

MeasureTime frame
Pain Visual Analogue Scale;

Secondary

MeasureTime frame
Adverse reactions of opioids;

Countries

China

Contacts

Public ContactLiu Xicheng

Shenzhen People's Hospital

flameliu@sina.com+86 137 5116 8960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026